CryoShot Canine

Indication: Canine osteoarthritis and tendinopathy
Technology Platform: Canine adipose-derived allogeneic mesenchymal stem cells (MSCs)

Product pipeline

The pipeline progress of CryoShot Canine

CryoShot is a cell therapy technology for the treatment of canine osteoarthritis and other musculoskeletal disorders.

CryoShot is made from expanded allogeneic MSCs from canine adipose tissue. CryoShot works by reducing inflammation and promoting healing and repair in the damaged or diseased tissue.

Points of difference

CryoShot is one of the new generation cell therapy treatments for osteoarthritis. CryoShot differs from other MSC therapies due to the considerable cost benefits of its manufacturing process. CryoShot manufacture has demonstrated the capability to produce commercial quantities of doses of cells from a single donor, which has many knock on benefits. Other traditional treatments for conditions such as osteoarthritis have been palliative pain medications. CryoShot is aimed at arresting the development and progression for osteoarthritis, as well as providing long-term pain release from a single intra-articular injection.

Next steps for CryoShot

We will continue our discussions with parties for commercialisation opportunities.